XPose Therapeutics

XPose Therapeutics is a biotechnology company focused on structure-based drug discovery for oncology. The company utilizes its proprietary XPose platform, which leverages high-throughput X-ray crystallography to identify and characterize cryptic binding pockets on previously undruggable protein targets. Originally incubated by Cullinan Oncology (now Cullinan Therapeutics), XPose focuses on developing small molecule inhibitors, with a primary emphasis on targets within the DNA damage response (DDR) pathway. Its lead program is a small molecule inhibitor of the WRN helicase, intended for the treatment of microsatellite instability-high (MSI-H) tumors. By providing high-resolution structural insights, XPose aims to accelerate the development of precision medicines for cancer patients.